|Bid||2.61 x 10000|
|Ask||2.75 x 2300|
|Day's Range||2.61 - 2.89|
|52 Week Range||1.46 - 3.38|
|PE Ratio (TTM)||-11.99|
|Earnings Date||Aug 28, 2017 - Sep 1, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||2.85|
Biomerica Inc. today announced it will present at the 18th Annual B. Riley institutional investor conference being held May 24-25, 2017 in Santa Monica, CA.Zackary Irani, Chief Executive Officer of Biomerica, ...
Revenue from Asia was $448k, up 22% from $367k in Q3 2016 (i.e. Europe has not been nearly as positive which saw sales fall 20% in fiscal 2016 and shed another 7% through the first half of fiscal 2017. But while one quarter does not make a trend, the most recent period bucked the prior 18-months of disappointing sales. Q3 ’17 European revenue of $654k was 20% better than the prior year number, up 41% from Q2 and the highest since Q4 2015. While Biomerica has never provided much in the way of detailed trends effecting revenue, they do note in the Q3 10-Q that an increase in sales of clinical laboratory products benefitted both their Asian and European segments. As we noted in previous updates, we viewed recent signs of European revenue stabilizing around ~$500k/quarter as encouraging relative to the potential for this territory to return to positive growth in the coming (i.e.
Categories: Yahoo FinanceGet free summary analysis Biomerica, Inc. reports financial results for the quarter ended February 28, 2017. Highlights Summary numbers: Revenues of USD 1.50 million, Net Earnings of USD -0.30 million. Gross margins widened from 25.30% to 29.96% compared to the same period last year, operating (EBITDA) margins now -17.68% from -15.49%. Change in operating cash ... Read more (Read more...)